Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

bendamustine

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

DNA replication inhibitor

Related drugs:

‹

›

No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	bendamustine Sensitive: A1 - Approval bendamustine Sensitive : A1	bendamustine Sensitive: A1 - Approval bendamustine Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	bendamustine Sensitive: A1 - Approval bendamustine Sensitive : A1	bendamustine Sensitive: A1 - Approval bendamustine Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	carboplatin + etoposide oral + bendamustine Sensitive: A2 - Guideline carboplatin + etoposide oral + bendamustine Sensitive : A2	carboplatin + etoposide oral + bendamustine Sensitive: A2 - Guideline carboplatin + etoposide oral + bendamustine Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	CD20 inhibitor + bendamustine Sensitive: A2 - Guideline CD20 inhibitor + bendamustine Sensitive : A2	CD20 inhibitor + bendamustine Sensitive: A2 - Guideline CD20 inhibitor + bendamustine Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	capecitabine + bendamustine Sensitive: C2 – Inclusion Criteria capecitabine + bendamustine Sensitive : C2	capecitabine + bendamustine Sensitive: C2 – Inclusion Criteria capecitabine + bendamustine Sensitive : C2
CD69 overexpression	Chronic Lymphocytic Leukemia	CD69 overexpression	Chronic Lymphocytic Leukemia	bendamustine Resistant: D – Preclinical bendamustine Resistant : D	bendamustine Resistant: D – Preclinical bendamustine Resistant : D